8Pitt B.Segal R.maritines FA.et al.Randomised trial of Losartan versus Captropril in patients over 65 with heart failure[J],Lancet 1997,349(12) :747-752.
9Jorde UP.Ennezat PV.Lisker J.et al.Maximally recommended doses of angiotensin-conveting enzyme(ACE)Inhibitor do not completely prevent ACE-mediated formation of Angiotensin Ⅱ in chronic heart failure[J].Circulation 2000,101 ( 8) : 844-846.
10Yamamoto S.Hayahi N.Kometuim M.et al.Pharmacalogical profile of Valsartan an non-peptide angiotenain Ⅱ type 1 receptor antagonist 5th commication:hemodynamic effects of Valsartan in dog heart failure models[J].Arzneimittelforsch.1997.47(5):630-634.
3Sasayama S, Matsumori A. Role of cytokine in the syndrome of heart failure[ J]. Intered, 1996,35 ( 1 ) :60-63.
4Kelly RA, Smith TW. Cytokines and cardiac contractile function[ J ].Circulation, 1997,95 (4) :778-781.
5Chung O,Csikos T,Unger T. Angiotensin Ⅱ recceptor pharmacology and AT2 recptors[ J] .J Hum Hypertens, 1999,12( Suppl 1 ) :11-20.
6Chung O, Kuhl H, Stoll I, et al. Physiological and pharmacological implications of AT1 receptors versus AT2 recptors[ J]. Kidney Int ,1998,67 ( Suppl 1 ) :95-99.
7Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure:the eytokiue hypothesis[ J ]. J Cardiol Fail, 1996,2 (3) :243-249.
8Semeri GG, Boddi M, Cecioni I, et al. Cardiac angiotensin Ⅱ formation in the clinical course of heart failure and its relationship with left ventricular function[J]. Circ Res.2001.88(9) :961-968.
9Brexler H, Gayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure[ J]. Am J Cardiol, 1992,69(19) :1596.
10Kiely DG,Cargill RI,Struthess AD,et al. Cardiopulmonary effects of endothelin-1 in man [J ]. Cardiovase Res, 1997,33 (5) :378-382.
